We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Immune Biomarkers Predict Early Death in HIV Patients with TB

By LabMedica International staff writers
Posted on 23 Feb 2015
Print article
Image: The NucliSENS Easy Q Real-time Rapid Nucleic Acid Sequence Based Amplification Platform (Photo courtesy of BioMérieux).
Image: The NucliSENS Easy Q Real-time Rapid Nucleic Acid Sequence Based Amplification Platform (Photo courtesy of BioMérieux).
Doctors treating patients battling both human immunodeficiency virus (HIV) and tuberculosis (TB), many of whom live in Africa, are faced with the decision when to start those patients on antiretroviral therapy (ART) while they are being treated with antibiotics for active TB disease.

Some patients fare well on both interventions, with the immune system in check and the TB controlled while others undergo complications from TB, such as paradoxical immune reconstitution inflammatory syndrome (IRIS), a worsening of TB symptoms despite response to therapy, while still others experience immune failure and early death.

Scientists at the Perelman School of Medicine (Philadelphia, PA, USA) undertook a prospective cohort study at 22 public clinics and the main public hospital in Gaborone, Botswana, in ART-naive adults, aged ≥21 years, with advanced HIV (CD4 cell counts ≤125 cells per μL) and pulmonary tuberculosis. Patients were classified as having tuberculosis-associated IRIS, early mortality, or survival without a diagnosis of tuberculosis-associated IRIS (controls), on the basis of outcomes recorded in the six months after ART initiation.

Blood was collected at baseline and week four of ART for HIV viral load (NucliSENS Easy Q HIV-1; BioMérieux; Marcy l'Etoile, France), plasma, and peripheral blood mononuclear cells. The team used a 29-cytokine, chemokine, and growth-factor magnetic-bead Luminex panel (EMD Millipore; Billerica, MA, USA) to measure immune biomarkers.

The investigators found that lower levels of eight biomarkers, including interleukin 6 (IL-6), IL-15 and granulocyte-macrophage colony-stimulating factor (GM-CSF), pre-ART were independently associated with an increased risk of IRIS, while higher levels of monocyte chemotactic protein 1 (MCP-1) and tumor necrosis factor-alpha (TNFα) were independently associated with an increased risk of death. However, IRIS and early mortality patients both experienced rapid increases in immune activation and inflammation after initiating ART. Four biomarkers, including IL-6, TNF-alpha, and granulocyte-colony stimulating factor (G-CSF), were independently associated with an increased risk of TB-IRIS, and five biomarkers were associated with an increased risk of death, including interleukin-1 receptor antagonist (IL-1RA) and G-CSF.

The magnitude of early immune recovery, the CD4 cell count, differed drastically between the two after being in ART, as well as underscoring the need for a personalized approach in these two groups. Those who initiated ART and died early had an increase in inflammation without the immune system rebounding enough to control the TB, while IRIS patients recovered more quickly. Gregory P. Bisson, MD, MSCE, a senior author of the study said, “The differences between the two groups, which haven’t been shown before, should influence future studies in this vulnerable population, as interventions that seek to prevent IRIS could inadvertently be increasing the risk of death. In this population, it’s important to study treatments that can decrease inflammation while promoting functional immune recovery.”

Related Links:

Perelman School of Medicine  
BioMérieux  
EMD Millipore 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.